Aspects and embodiments of the present disclosure provide therapeutic methods and compositions comprising interleukin 12 (IL-12) useful for improving hematopoietic recovery HSCT transplantation in an individual. In particular, the disclosure herein provides exemplary methods and compositions that include the recovery and survival of peripheral blood cells that are effectively increased as much as BMCT in IL-12-promoted hematopoietic and lethally irradiated mice, since rHuIL- Indicating increased HSC engraftment. We identified IL-12R [beta] 2 expressing cells in irradiated mouse bone marrow, a potential target of IL-12. Administration of rMuIL-12 increased the number of Lin- cells expressing IL-12R? 2 in mouse bone marrow, indicating that bone marrow HSC and niche cells are direct targets of rMuIL-12 and that hematopoietic-promoting activity of rMuIL- Lt; RTI ID = 0.0 IL-12 / RTI receptor on HSCs. Finally, we have identified the expression of IL-12 [beta] 2 on human bone marrow lin- and CD34 + cells, indicating the potential role of IL-12 in human transplantation.
展开▼
